Jie Zang, Feng Mao1, Hao Wang, Jingjing Zhang, Qingxing Liu, Li Peng1, Fang Li, Lixin Lang2, Xiaoyuan Chen2, Zhaohui Zhu. 1. Department of Breast Surgery, PUMC Hospital, Chinese Academy of Medical Science and PUMC, Beijing, People's Republic of China. 2. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD.
Abstract
BACKGROUND: This prospective pilot study investigated the value of Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor, in evaluation of breast cancer. METHODS: Thirty-five women in suspicion of breast cancer based on mammography or ultrasonography were recruited with informed consent. They underwent PET/CT scans 30 minutes after intravenous injection of Ga-NOTA-RM26 in a dose of 1.85 MBq (0.05 mCi) per kilogram body weight within 1 week before surgery. The Ga-NOTA-RM26 uptake was correlated with the pathological and immunohistochemical findings. RESULTS: Ga-NOTA-RM26 positivity was found correlated with estrogen receptor (ER) expression (P = 0.006) and menstrual status (P = 0.019). In 34 patients diagnosed with breast cancer, the SUVmax was found significantly higher in the ER-positive breast cancer (4.97 ± 1.89) than in the ER-negative breast cancer (2.78 ± 0.65, P < 0.001). Ga-NOTA-RM26 was also found accumulated in normal breast tissue, with the SUVmax significantly higher in patients at the secretory phase of menstrual cycle (2.27 ± 0.71) than in those at the nonsecretory phase (1.59 ± 0.49, P = 0.017) and postmenopause (1.43 ± 0.44, P = 0.002). If the secretory phase patients were excluded, the sensitivity, specificity, and accuracy for differentiation of breast cancer from breast tissue increased from 85.3%, 86.8%, and 86.1% to 100%, 90.9%, and 95.5%, respectively. CONCLUSIONS: This pilot study indicates that the diagnostic accuracy of Ga-NOTA-RM26 PET/CT in breast cancer may correlate with ER expression and menstrual status of the patient. It may be better to avoid performing this examination during the menstrual secretory phase to reduce physiological uptake in normal breast tissue.
BACKGROUND: This prospective pilot study investigated the value of Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor, in evaluation of breast cancer. METHODS: Thirty-five women in suspicion of breast cancer based on mammography or ultrasonography were recruited with informed consent. They underwent PET/CT scans 30 minutes after intravenous injection of Ga-NOTA-RM26 in a dose of 1.85 MBq (0.05 mCi) per kilogram body weight within 1 week before surgery. The Ga-NOTA-RM26 uptake was correlated with the pathological and immunohistochemical findings. RESULTS:Ga-NOTA-RM26 positivity was found correlated with estrogen receptor (ER) expression (P = 0.006) and menstrual status (P = 0.019). In 34 patients diagnosed with breast cancer, the SUVmax was found significantly higher in the ER-positive breast cancer (4.97 ± 1.89) than in the ER-negative breast cancer (2.78 ± 0.65, P < 0.001). Ga-NOTA-RM26 was also found accumulated in normal breast tissue, with the SUVmax significantly higher in patients at the secretory phase of menstrual cycle (2.27 ± 0.71) than in those at the nonsecretory phase (1.59 ± 0.49, P = 0.017) and postmenopause (1.43 ± 0.44, P = 0.002). If the secretory phase patients were excluded, the sensitivity, specificity, and accuracy for differentiation of breast cancer from breast tissue increased from 85.3%, 86.8%, and 86.1% to 100%, 90.9%, and 95.5%, respectively. CONCLUSIONS: This pilot study indicates that the diagnostic accuracy of Ga-NOTA-RM26 PET/CT in breast cancer may correlate with ER expression and menstrual status of the patient. It may be better to avoid performing this examination during the menstrual secretory phase to reduce physiological uptake in normal breast tissue.
Authors: Simone U Dalm; Anieta M Sieuwerts; Maxime P Look; Marleen Melis; Carolien H M van Deurzen; John A Foekens; Marion de Jong; John W M Martens Journal: J Nucl Med Date: 2015-08-06 Impact factor: 10.057
Authors: Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Stefan Kneifel; Maria-Luisa Tamma; Beatrice Waser; Renzo Cescato; Jean Claude Reubi; Helmut R Maecke Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova Journal: Pharmaceutics Date: 2021-01-30 Impact factor: 6.321
Authors: Kerstin Michalski; Lars Kemna; Jasmin Asberger; Anca L Grosu; Philipp T Meyer; Juri Ruf; Tanja Sprave Journal: Cancers (Basel) Date: 2021-12-03 Impact factor: 6.639
Authors: Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen Journal: Front Endocrinol (Lausanne) Date: 2021-09-01 Impact factor: 5.555
Authors: Barbara Salvatore; Maria Grazia Caprio; Billy Samuel Hill; Annachiara Sarnella; Giovanni Nicola Roviello; Antonella Zannetti Journal: Cancers (Basel) Date: 2019-10-22 Impact factor: 6.639